3 ms·
I heard this on a BBC radio 4 radio program related to disability issues aired on either a Tuesday or Thursday around 9pm in around 2014/2015.
by gvjddbnvdrbv 7y ago
I heard this on a BBC radio 4 radio program related to disability issues aired on either a Tuesday or Thursday around 9pm in around 2014/2015.
- DanBC 7y ago2011? https://www.bbc.co.uk/programmes/b016817t https://www.bbc.co.uk/programmes/b016817t Avastin / Lucentis does not support the point being made. Lucentis, a very expensive medication, was both licenced for AMD and was approved by NICE for that use. Avastin is identical, but was not licenced for AMD and so NICE was not able to recommend its use for AMD. Doctors were using Avastin off label, and they wanted the government to force Avastin to be licenced for AMD which would have allowed it to be recommended by NICE. The makers of Avastin and Lucentis fought this in the courts for years, and took action against NHS Trusts using Avastin off-label. The NHS won that legal case. https://www.bbc.co.uk/news/health-30138097 https://www.bbc.co.uk/news/health-30138097 https://www.hsj.co.uk/finance-and-efficiency/breaking-nhs-wins-landmark-legal-battle-against-drug-companies/7023422.article https://www.hsj.co.uk/finance-and-efficiency/breaking-nhs-wi... There is a problem of people going blind while waiting for treatment, but this is related to cataracts and glaucoma, not AMD, and it has nothing to do with NICE (who are the organisation that decides about cost effectiveness) and everything to do with a government that has chosen to de-fund the NHS.
- gvjddbnvdrbv 7y ago> There is a problem of people going blind while waiting for treatment, but this is related to cataracts and glaucoma This is what I was referring to. The cost decision involved was of course not to have the follow up appointments sooner.